Off Label NCCN denied as not medically necessary by Humana?

Humana's specific coverage criteria for off label nccn are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Off-Label (NCCN-Supported) Drug on Medical-Necessity Grounds

A medical-necessity denial from Humana means their clinical reviewer concluded that the requested drug does not meet the plan's definition of medically necessary for your diagnosis — typically because the reviewer decided an alternative treatment is adequate, or that the clinical evidence does not support this choice at this point in your care. For NCCN-supported off-label oncology drugs, this denial often reflects a mismatch between the plan's internal criteria and the expert consensus reflected in the NCCN Compendium.

## Why This Is Appealable

Humana's clinical review criteria are not the only recognized standard. NCCN Compendium listings carry formal recognition under multiple state and federal coverage frameworks. If your prescriber's clinical judgment — supported by an applicable NCCN category listing — is that this drug is the appropriate next step, the plan's contrary conclusion can and should be challenged with a structured evidentiary response.

## Federal Appeal Framework

• Internal appeal: File within the window stated on your EOB. Request a copy of all clinical guidelines and criteria Humana used. Ask that your appeal be reviewed by a physician in the same specialty as your prescriber.
• External review (ACA §2719): If the internal appeal is denied, you have the right to IRO review. The standard deadline is approximately four months from the final internal denial; expedited review is available for urgent clinical situations.
• ERISA §503 (employer plans): You are entitled to a full-and-fair review with access to all documents used in the decision.

## Documentation to Gather

1. Diagnosis confirmation — pathology, imaging, genetic/molecular testing relevant to drug selection. 2. Clinical severity and trajectory — chart notes documenting disease progression, symptom burden, and performance status. 3. Prior treatment history — complete dated list of treatments tried, with documented outcomes and reasons for discontinuation. 4. NCCN compendium printout — the applicable NCCN listing for this drug and indication, showing the current category. 5. Prescriber medical-necessity letter — a thorough letter explaining why alternatives are inadequate in your specific case and why this drug is the medically necessary choice.

## Criteria-Mapping Structure

Obtain Humana's published medical-necessity definition and clinical coverage policy for this drug or drug class. Create a side-by-side table: Humana's stated criteria on the left, the corresponding chart evidence on the right. Each row should reference a specific document (e.g., clinic note dated, lab result dated). Submit this table as the core of your written appeal.